Alfred Altomari
CIK 1285644 · Chief Executive Officer · last filed 2024-08-26
Alfred Altomari is a Chief Executive Officer who has filed 82 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for INSM, was dated Aug 13, 2025. Across all open-market trades the lifetime net is −$1.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $8.0M across reported positions. 11 SEC filings were submitted jointly with Recro Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INSM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
101 POOR FARM ROAD
PRINCETON, NJ 08540
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INSM | Director | 69,495 | $115.08 | $8.00M | -$1.37M | 18 | 2024-05-15 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Chief Executive Officer | 38,786 | $1.51 | $58.6K | $332.7K | 31 | 2023-06-30 |
| Baudax Bio, Inc. (BXRX) Delisted | Director | 84 | $0.02 | $2 | $17.0K | 5 | 2021-04-08 |
| Societal CDMO, Inc. (REPH) Delisted | Director | 44,196 | $2.09 | $92.4K | $9.8K | 10 | 2019-12-09 |
| DUSA | Director | 0 | $57.42 | $0 | $13.2K | 6 | 2012-12-20 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | -$199.9K | 6 | 2011-06-20 |
| BARRIER THERAPEUTICS INC (BTRX) Delisted | Chief Executive Officer | 0 | — | — | $0 | 3 | 2008-08-06 |
Recent Filings
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-13 | INSM | Notice (144) | −13,600 | -$1.65M | EDGAR |
| 2025-06-10 | INSM | Notice (144) | −25,000 | -$1.77M | EDGAR |
| 2024-08-26 | — | Disp (D) | −47,749 | -$72.6K | |
| 2024-05-15 | INSM | Grant (A) | +13,162 | $0 | EDGAR |
| 2023-06-30 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +46,463 | $0 | EDGAR |
| 2023-05-15 | INSM | Grant (A) | +13,192 | $0 | EDGAR |
| 2022-11-14 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-29 | AGILE THERAPEUTICS INC (AGRX) Delisted | Buy (P) | +50,000 | $22.5K | EDGAR |
| 2022-05-13 | INSM | Grant (A) | +14,645 | $0 | EDGAR |
| 2022-01-20 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.